GENINCODE PLC LS -01 Total Assets
GENINCODE PLC LS -01 total assets. Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) holds total assets worth €2.38 Million EUR (≈ $2.78 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 9PL market cap overview for the company's overall valuation and market capitalisation.
Total Assets of GENINCODE PLC LS -01 (2021–2025)
Total assets of GENINCODE PLC LS -01 from 2021 to 2025. This chart illustrates how GENINCODE PLC LS -01's total assets have evolved over time, based on quarterly financial data. See today's stock price for GENINCODE PLC LS -01 for real-time trading data and today's change.
GENINCODE PLC LS -01 - Asset Composition Analysis
GENINCODE PLC LS -01 Total Assets Breakdown (December 2025)
GENINCODE PLC LS -01 total assets breakdown as of December 2025. GENINCODE PLC LS -01's total assets of €2.38 Million consist of 85.9% current assets and 14.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.8% |
| Accounts Receivable | €857.00K | 36.1% |
| Inventory | €73.00K | 3.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €98.00K | 4.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how GENINCODE PLC LS -01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 9PL current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GENINCODE PLC LS -01's current assets represent 85.9% of total assets in 2025, a decrease from 98.4% in 2021.
- Cash Position: Cash and equivalents constituted 34.8% of total assets in 2025, down from 95.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 36.1% of total assets.
GENINCODE PLC LS -01 Competitors by Total Assets
Key competitors of GENINCODE PLC LS -01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonza Group AG
SW:LONN
|
Switzerland | CHF18.26 Billion |
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.42 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
GENINCODE PLC LS -01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 1.53 | 2.60 |
| Quick Ratio | 0.90 | 1.44 | 2.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-158.00K | €727.00K | €2.36 Million |
GENINCODE PLC LS -01 - Advanced Valuation Insights
This section examines the relationship between GENINCODE PLC LS -01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.70 |
| Latest Market Cap to Assets Ratio | 2.22 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | €2.38 Million |
| Market Capitalization | $5.28 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values GENINCODE PLC LS -01's assets at a significant premium (2.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: GENINCODE PLC LS -01's assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GENINCODE PLC LS -01 (2021–2025)
The table below shows the annual total assets of GENINCODE PLC LS -01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.38 Million ≈ $2.78 Million |
-10.74% |
| 2024-12-31 | €2.66 Million ≈ $3.11 Million |
-36.38% |
| 2023-12-31 | €4.19 Million ≈ $4.89 Million |
-64.52% |
| 2022-12-31 | €11.80 Million ≈ $13.79 Million |
-22.44% |
| 2021-12-31 | €15.21 Million ≈ $17.78 Million |
-- |
About GENINCODE PLC LS -01
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of fa… Read more